Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

Inclusion Criteria: * Adult patients ≥18 years of age * Receiving outpatient in-center hemodialysis for ESKD at least TIW (prescribed) * Currently receiving EPO (active administration, not on HOLD) * Less than or equal to 0.75 g/d difference between last 2 Hgb values prior to Screening, with neither Hgb \<9 g/dL * Average of last 2 Hgb between 9-11.4 g/dL (inclusive) prior to Screening * Central Screening Hgb 9-11.4 g/dL (inclusive) * Central Screening transferrin saturation greater than or equal to 20% * Central Screening serum ferritin greater than or equal to 100 ng/mL * Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure Exclusion Criteria: * Contraindication to receive vadadustat per United States Prescribing Information (USPI) including Screening liver function tests greater than 3x the upper limit of normal (ULN) * Electronic Medical Record (EMR)-documented history of cirrhosis or active, acute liver disease * EMR-documented history of currently active malignancy excluding non-melanomatous skin cancer and in-situ cervical cancer * Concomitant use of HIF-PHI or OAT1/OAT3 inhibitors (probenecid, rifampicin, gemfibrozil, or teriflunomide) * Unable to comply with study requirements or in the opinion of a healthcare provider or member of the central study team, not clinically stable to participate in the study * Documented unplanned absence from dialysis greater than …